- In
accordance with Israeli regulations, demand letter has been sent to MDGS
and meeting of company shareholders must be held within 21 days of
letter’s date
- Pure
Capital Ltd. says that it is committed to raising MDGS shareholder value
through the process of replacing internal members of the board of
directors
- Replacement
nominees are led by Professor Benad Goldwasser, a urological surgeon,
inventor and entrepreneur; all nominees have been vetted, according to
Pure Capital
Privately-held investment firm Pure Capital Ltd. yesterday
announced that it has acquired 217,696 ADRs of Medigus Ltd. (NASDAQ: MDGS)
(TASE: MDGS), bringing its total ownership stake to greater than five percent
of the Israeli medical device company (http://ibn.fm/AVCmk). In accordance with Israeli
regulations, Pure Capital has sent a letter to Medigus’ CEO, board chairman and
board of directors seeking an immediate general assembly meeting of the MDGS
shareholders and the dismissal of its internal members of the board.
In the letter, Pure Capital details a number of recent
corporate actions that it believes have been harmful to the company’s
shareholders. They include continual capital consolidations and capital raises
under unfavorable terms. Further, Pure Capital has asked MDGS to avoid raising
capital, making public or private offerings and executing disposition of assets
until the meeting has taken place.
In a news release issued earlier this week, Pure Capital
noted that it is committed to substantially increasing MDGS’s shareholder value
and fully replacing the members of its board. According to Israeli regulations,
the requested meeting must be held no later than 21 days from the date of the
letter of demand.
A team of replacement nominees, as detailed by Pure Capital,
is led by Professor Benad Goldwasser. He is a urological surgeon and co-founder
of Medinol Ltd., an Israeli medical device company. He and the other nominees
have been carefully vetted and were selected after a thorough due diligence
process by Pure Capital.
Pure Capital has led various transactions and capital raises
totaling over $200 million over the past two years in the U.S., Canada and
Israel.
MDGS is a medical device company specializing in developing
innovative imaging solutions and minimally invasive endosurgical tools. The
company also developed the MUSE™ system endoscopic device, which is designed
for the treatment of gastroesophageal reflux disease (GERD).
For more information, visit the company’s website at www.Medigus.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
